These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37151285)

  • 1. Somatic mutation profiling, tumor-infiltrating leukocytes, tertiary lymphoid structures and PD-L1 protein expression in HER2-amplified colorectal cancer.
    Liu XT; Kou ZY; Zhang H; Dong J; Zhang JH; Peng YJ; Ma SM; Liang L; Meng XY; Zhou Y; Yang J
    PeerJ; 2023; 11():e15261. PubMed ID: 37151285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
    Yang L; Liu S; He W; Xiong Z; Xia L
    BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
    Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
    Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
    Goldmann T; Marwitz S; Nitschkowski D; Krupar R; Backman M; Elfving H; Thurfjell V; Lindberg A; Brunnström H; La Fleur L; Mezheyeuski A; Mattsson JSM; Botling J; Micke P; Strell C
    Cancer Immunol Immunother; 2021 Sep; 70(9):2577-2587. PubMed ID: 33576873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
    Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis.
    Lee KS; Kim BH; Oh HK; Kim DW; Kang SB; Kim H; Shin E
    Cancer Sci; 2018 Sep; 109(9):2957-2969. PubMed ID: 29949671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of the immunogenicity and tumor immune microenvironment in
    Wang Q; Mao Z; Li W; Wang S; Wang L; Chen L; Yang Z; Fu X; Jiang P; Bai Y; Xu L; Zhang S; Hou Y; Jia X; Jiang L; Liu M; Zhang G; Jiang Y; Guo H
    Front Immunol; 2022; 13():1042072. PubMed ID: 36591290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer.
    Zhang Y; Li J; Yang F; Zhang X; Ren X; Wei F
    J Leukoc Biol; 2022 Dec; 112(6):1591-1603. PubMed ID: 35501298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
    Wang JL; Yu T; Sun TT; Feng Y; Xiong H; Fang JY
    Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
    Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
    Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer.
    Wang Q; Shen X; An R; Bai J; Dong J; Cai H; Zhu H; Zhong W; Chen W; Liu A; Du J
    Front Immunol; 2022; 13():962056. PubMed ID: 36189233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.